Heart - McMaster Experts

publication venue for

98 Non-specific chest pain hospital admissions and readmissions for serious cardiovascular events in the United States 2019
25 Managing cardiovascular disease (CVD) risk factors in stroke and tia patients as part of an integrated community based preventive cardiology programme 2018
81 Innovative Management of Low Risk Patients with Chest Pain Presenting to The Emergency Department 2016
REVERSAL OF THE ANTI-PLATELET EFFECTS OF ASPIRIN AND CLOPIDOGREL 2012
159 Pilot Study exploring the regional repolarisation instability index in relation to myocardial heterogeneity and prediction of ventricular arrhythmia and death 2011
GENETIC LOCI INFLUENCING C-REACTIVE PROTEIN LEVELS AND CORONARY HEART DISEASE RISK: RESULTS OF GENETIC ASSOCIATION AND MENDELIAN RANDOMISATION STUDY WITH META-ANALYSIS IN 80 614 PEOPLE 2009
Monocyte gene expression profiling in individuals with contrasting familial risk for premature myocardial infarction 2008
Heart-type fatty acid binding protein predicts mortality in patients with sinus rhythm and left ventricular systolic dysfunction 2007
The risk associated with diabetes mellitus in patients with preserved and low ejection fraction heart failure. An analysis of the candesartan in heart failure: Assessment of reduction in mortality and morbidity programme 2007
Evaluating the health economic impact of clopidogrel for acute coronary syndromes in five countries, based on the CURE study 2003
Long term follow up of patients with acute coronary syndromes without ST elevation: PrAIS-UK 2003
REDUCTION IN MAJOR MORBIDITY AND MORTALITY BY HEPARIN IN ACUTE MYOCARDIAL-INFARCTION 1989
A STUDY OF ASPIRIN OR SULPHINPYRAZONE IN UNSTABLE ANGINA 1985
BETA-BLOCKADE PRODUCES GREATER ATTENUATION OF EXERCISE TACHYCARDIA IN THE DENERVATED HUMAN-HEART 1985
INCREASED SENSITIVITY OF THE DENERVATED HUMAN-HEART TO ISOPRENALINE BEFORE AND AFTER BETA-BLOCKADE 1985
IMPROVEMENT OF ELECTROCARDIOGRAM BY CHRONIC BETA-ADRENOCEPTOR BLOCKADE DURING HEALING PHASE OF CLINICAL AND EXPERIMENTAL MYOCARDIAL-INFARCTION 1980
NORMALIZATION OF ELECTROCARDIOGRAM IN SURVIVORS OF MYOCARDIAL-INFARCTION ON BETA-BLOCKERS 1979
SERUM MYOGLOBIN DETERMINATION IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION 1979
Advancing women's cardiovascular health: an international lens on the Joint British Cardiovascular Societies' consensus statement.. 110:1289-1290. 2024
Reference ranges for ambulatory heart rate measurements in a middle-aged population. 110:831-837. 2024
Regional variations in heart failure: a global perspective. 110:11-18. 2024
Fixed dose combination therapies in primary cardiovascular disease prevention in different groups: an individual participant meta-analysis. 109:1372-1379. 2023
Patient clusters and cost trajectories in the Swiss Atrial Fibrillation cohort. 109:763-770. 2023
Trimethylamine-N-oxide is associated with cardiovascular mortality and vascular brain lesions in patients with atrial fibrillation. 109:396-404. 2023
Representation of women in heart failure trials: does it matter?. 108:1508-1509. 2022
Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. 108:1342-1350. 2022
Sex-specific differences in adverse outcome events among patients with atrial fibrillation. 108:1445-1451. 2022
Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis. 108:1296-1302. 2022
Overweight and incident hypertension: does age of onset matter?. 108:664-665. 2022
COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction. 108:458-466. 2022
Association between routine measures of graft function and mortality in heart transplant recipients. 108:307-311. 2022
Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses. 107:1962-1973. 2021
Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease. 107:1739-1747. 2021
Bias: does it account for low surgical rates in women with infective endocarditis?. 107:1688-1689. 2021
Response to ‘Adverse cardiac outcomes in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors’. 107:1680.2-1681. 2021
Clinical practice guideline for transcatheter versus surgical valve replacement in patients with severe aortic stenosis in Latin America. 107:1450-1457. 2021
Patient values and preferences on valve replacement for aortic stenosis: a systematic review. 107:1289-1295. 2021
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. 107:1130-1137. 2021
Comparative effectiveness of oral anticoagulants in everyday practice. 107:962-970. 2021
Discontinuation of oral anticoagulation in atrial fibrillation and risk of ischaemic stroke. 107:542-548. 2021
Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease. 107:667-673. 2021
Variations in knowledge, awareness and treatment of hypertension and stroke risk by country income level. 107:282-289. 2021
Associations of symptoms and quality of life with outcomes in patients with atrial fibrillation. 106:1847-1852. 2020
Can you feel the beat? How to define reference ranges for ambulatory heart rhythm monitoring. 106:1708-1709. 2020
Percutaneous mitral commissurotomy versus surgical commissurotomy for rheumatic mitral stenosis: a systematic review and meta-analysis of randomised controlled trials. 106:1094-1101. 2020
ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis. 106:738-745. 2020
Pregnancy outcomes in women with significant valve disease: a systematic review and meta-analysis. 106:512-519. 2020
Left atrial dimension and cardiovascular outcomes in patients with and without atrial fibrillation: a systematic review and meta-analysis. 105:1884-1891. 2019
High-sensitivity troponin testing months after an acute coronary syndrome: noise or notable results. 105:1688-1690. 2019
Qualitative study of cardiologists’ perceptions of factors influencing clinical practice decisions. 105:749-754. 2019
Digoxin and clinical outcomes in the Global Rheumatic Heart Disease Registry. 105:363-369. 2019
Meta-analysis: mistake or milestone in medicine?. 104:1559-1561. 2018
Perioperative management of anticoagulant and antiplatelet therapy. 104:1461-1467. 2018
Improving medication adherence in patients with cardiovascular disease: a systematic review. 104:1238-1243. 2018
Prognostic validation of a non-laboratory and a laboratory based cardiovascular disease risk score in multiple regions of the world. 104:581-587. 2018
Implantable cardiac defibrillator and mortality in non-ischaemic cardiomyopathy: an updated meta-analysis. 104:230-236. 2018
Predictors of 1-year mortality in heart transplant recipients: a systematic review and meta-analysis. 104:151-160. 2018
Menopausal age, postmenopausal hormone therapy and incident atrial fibrillation. 103:1954-1961. 2017
Menopausal age, postmenopausal hormone therapy and incident atrial fibrillation. 103:1954-1961. 2017
Structural valve deterioration after transcatheter aortic valve implantation. 103:1899-1905. 2017
Effects of dabigatran according to age in atrial fibrillation. 103:1015-1023. 2017
Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. 103:307-314. 2017
Valvular heart disease and pregnancy part II: management of prosthetic valves. 103:244-252. 2017
Evidence, experts, trustworthy guidelines and WikiRecs. 103:3-5. 2017
Validation of presentation and 3 h high-sensitivity troponin to rule-in and rule-out acute myocardial infarction. 102:1270-1278. 2016
Cochrane corner: early statin therapy in acute coronary syndromes—what is the clinical benefit?. 102:653-654. 2016
Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis. 102:590-596. 2016
Dabigatran etexilate and reduction in serum apolipoprotein B. 102:57-62. 2016
Clinical characteristics and outcomes of acute coronary syndrome patients with left anterior hemiblock. 100:1456-1461. 2014
Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. 100:1193-1200. 2014
Efficacy and safety of a routine early invasive strategy after fibrinolysis stratified by glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: a pre-specified subgroup analysis of the TRANSFER-AMI randomised controlled trial. 100:873-880. 2014
Determinants of effective heart failure self-care: a systematic review of patients’ and caregivers’ perceptions. 100:716-721. 2014
The evolving role of multimodality imaging in valvular heart disease. 100:336-346. 2014
Right ventricular function and survival following cardiac resynchronisation therapy. 99:722-728. 2013
Association between discharge heart rate and left ventricular adverse remodelling in ST segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. 99:556-561. 2013
Systems of care for ST-elevation myocardial infarction in India. 98:15-17. 2012
Relationship between QRS duration and left ventricular mass and volume in patients at high cardiovascular risk. 97:1766-1770. 2011
Six-year follow-up of a randomised controlled trial examining hospital versus home-based exercise training after coronary artery bypass graft surgery. 97:1169-1174. 2011
Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). 97:797-802. 2011
Quantitative troponin and death, cardiogenic shock, cardiac arrest and new heart failure in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS): insights from the Global Registry of Acute Coronary Events. 97:197-202. 2011
Non-invasive evaluation of myocardial fibrosis: implications for the clinician. 96:2016-2024. 2010
What do you say about risk?. 96:7-8. 2010
Education and risk for acute myocardial infarction in 52 high, middle and low-income countries: INTERHEART case-control study. 95:2014-2022. 2009
Potentially modifiable risk factors associated with myocardial infarction in China: the INTERHEART China study. 95:1857-1864. 2009
Atrial tissue Doppler imaging for prediction of new-onset atrial fibrillation. 95:835-840. 2009
Stroke prevention in atrial fibrillation: better use of anticoagulation and new agents will lead to improved outcomes. 95:95-97. 2009
Unilateral pulmonary vein stenosis secondary to idiopathic fibrosing mediastinitis. 94:776-776. 2008
Effect of valsartan compared with valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: the Val-MARC trial. 94:e13-e13. 2008
Epidemiology and causation of coronary heart disease and stroke in India. 94:16-26. 2008
Global burden of cardiovascular disease. 93:1175-1175. 2007
Antithrombotic treatment for peripheral arterial disease. 93:303-308. 2007
Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. 93:59-64. 2007
A cardiologist's guide to waist management. 92:865-866. 2006
Metoprolol prophylaxis against postoperative atrial fibrillation increases length of hospital stay in patients not on pre-operative blockers: the blocker length of stay (BLOS) trial. 90:941-942. 2004
Physiologic pacing: where pacing mode selection reflects the indication. 90:593-594. 2004
Lung function and aerobic capacity in adult patients following modified Fontan procedure. 85:295-299. 2001
Psychosocial components of cardiac recovery and rehabilitation attendance. 85:290-294. 2001
The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction. 84:142-148. 2000
The effect of sertraline on Autonomic Nervous System (ANS) regulation in post myocardial infarction. 83. 2000
Implications of the Heart Outcomes Prevention Evaluation (HOPE) for the treatment of patients at high cardiovascular risk; systolic versus diastolic pressure predictive value. 83. 2000
Antihypertensive drugs and foetal growth in hypertensive syndromes in pregnancy. 79. 1998
A double blind comparison of enoxaparin (a low molecular weight heparin) with standard heparin in the treatment of unstable coronary artery disease "The essence trial". 77. 1997
Double blind placebo controlled trial of short term transdermal scopolamine on heart rate variability in patients with chronic heart failure.. 76:137-143. 1996
Regional distribution and kinetics of [18F]6-flurodopamine as a measure of cardiac sympathetic activity in humans.. 75:29-34. 1996
Ventricular arrhythmias in long term survivors of orthotopic and heterotopic cardiac transplantation.. 59:648-652. 1988
Interrelation between donor and recipient heart rates during exercise after heterotopic cardiac transplantation.. 54:173-178. 1985
Variability of electrocardiographic and enzyme evolution of myocardial infarction in man.. 45:271-280. 1981
Heart rate and ectopic prematurity in relation to sustained ventricular arrhythmias.. 44:233-239. 1980
Value of electrocardiogram in predicting and estimating infarct size in man.. 42:286-293. 1979
Response of the left ventricle to nitroglycerin in patients with and without mitral regurgitation.. 36:357-361. 1974
Transient systolic hypertension after aortic valve replacement.. 34:227-231. 1972
Early rate of resolution of major pulmonary embolism. A study of angiographic and haemodynamic changes occurring in the first 24 to 48 hours.. 33:432-437. 1971

Heart Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)